Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TG4050 |
Synonyms | |
Therapy Description |
TG4050 is a vaccine consisting of modified Vaccinia virus Ankara (MVA) expressing tumor-specific neoantigens that may stimulate anti-tumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2637). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TG4050 | TG-4050|TG 4050 | TG4050 is a vaccine consisting of modified Vaccinia virus Ankara (MVA) expressing tumor-specific neoantigens that may stimulate anti-tumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2637). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04183166 | Phase I | TG4050 | A Clinical Trial Evaluating TG4050 in Head and Neck Cancer | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT03839524 | Phase I | TG4050 | A Trial Evaluating TG4050 in Ovarian Carcinoma. | Active, not recruiting | USA | FRA | 0 |